Triple-Positive and Asymptomatic: Does a Negative Aspirin Trial Actually Apply to Her
She's never had a clot, and her new antibody panel is above threshold on all three tests at once. The disagreement is whether a fourteen-year-old negative aspirin trial actually tells us anything about a patient who looks like her.
S.A., a 35-year-old woman, a high school counselor, with SLE diagnosed nine years ago (cutaneous and articular involvement, no renal or hematologic disease), had antiphospholipid antibody testing repeated as part of a routine annual panel and returned positive on all three assays — lupus anticoagulant, anticardiolipin IgG at high titer, and anti-beta-2-glycoprotein I IgG at high titer — confirmed on repeat testing twelve weeks later per classification criteria. She has never had a venous or arterial thrombotic event, no pregnancy morbidity, and no other traditional cardiovascular risk factors: she doesn't smoke, her blood pressure and lipid panel are both normal, and she has no family history of early thrombosis. She has been on hydroxychloroquine throughout her nine years of follow-up and remains on it today. She asked, when the results came back, whether this meant she “already has APS.” She does not: antibody positivity without a qualifying clinical event meets the laboratory criteria and not the classification, which makes her an aPL carrier rather than a patient with a syndrome, and puts everything that follows in the register of prevention rather than treatment.
Triple positivity — all three assays positive at high titer — is the specific antiphospholipid profile that the 2019 EULAR APS management recommendations flag as high-risk, carrying a materially higher annual thrombosis incidence than isolated single-antibody positivity. It also carries a specific recommendation rather than a general concern: those same 2019 recommendations advise prophylactic low-dose aspirin for asymptomatic carriers with a high-risk profile, which is the position her panel puts her in. That sits awkwardly beside APLASA, Erkan's 2007 trial and still the only randomized, placebo-controlled test of low-dose aspirin for primary thromboprophylaxis in asymptomatic aPL-positive individuals, which found no benefit — but APLASA randomized 98 people, stopped early for an unexpectedly low event rate, and was never enriched for triple-positive profiles the way hers is; a commentary on the trial published the following year said as much, calling for studies in exactly her stratum. A negative result in a broader, lower-risk population does not automatically transfer to a patient who sits in the specific high-risk stratum that trial was never large enough, or targeted enough, to study on its own.
Follow-up after a routine antibody panel came back
She's triple-positive at high titer on all three assays — lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I — which EULAR's own 2019 recommendations flag as the genuinely high-risk profile, not just ‘positive.’ EULAR's 2019 recommendations advise low-dose aspirin for exactly that profile. And APLASA, the one placebo-controlled aspirin trial we have, randomized 98 patients, stopped early for too few events, and was never enriched for triple-positive ones. A negative result in a broader population doesn't automatically tell us the answer for her specific stratum. I'd start low-dose aspirin.
I want to be careful here: no randomized trial has ever shown aspirin actually works for primary prophylaxis in asymptomatic aPL-positive patients, at any titer, in any subgroup — and I'll grant straight away that a EULAR recommendation graded on observational data and meta-analysis is not nothing, only that it isn't what we usually mean when we say the evidence supports something. Pointing out that APLASA wasn't enriched for her profile is a real observation, but it's an argument that we don't have disproof for her specific stratum — it isn't the same as having proof it helps her.
Aspirin's bleeding risk isn't zero either, and I don't think a population-mismatch argument alone should carry a treatment decision when the actual evidence for benefit, in anyone, doesn't exist yet.
You're right that we don't have positive trial data for her specific profile — I'm not going to pretend we do. But I don't think this has to stay a binary choice between aspirin and nothing. Statins carry a real, independent anti-thrombotic and anti-inflammatory signal in antiphospholipid-associated disease, separate from their cholesterol effect.
Given the genuine uncertainty on both sides, I'd have an honest conversation with her about starting low-dose aspirin given her risk profile, name the statin option as a real if earlier-stage consideration, and revisit both if her risk factors ever change.
Agreed: start low-dose aspirin after shared decision-making about the genuine uncertainty involved, continue hydroxychloroquine unchanged, and name the statin option explicitly in her chart as a real consideration to revisit rather than a settled recommendation.
Not agreed: whether the population-mismatch argument for aspirin was strong enough evidence to act on, given no trial has ever actually shown benefit in any aPL-positive subgroup — the pharmacologist's position wasn't overruled so much as outweighed by shared decision-making once the genuine absence of disproof for her specific profile was named plainly to her.